BR112022000944A2 - Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv - Google Patents

Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv

Info

Publication number
BR112022000944A2
BR112022000944A2 BR112022000944A BR112022000944A BR112022000944A2 BR 112022000944 A2 BR112022000944 A2 BR 112022000944A2 BR 112022000944 A BR112022000944 A BR 112022000944A BR 112022000944 A BR112022000944 A BR 112022000944A BR 112022000944 A2 BR112022000944 A2 BR 112022000944A2
Authority
BR
Brazil
Prior art keywords
hbv
treatment
hbv infection
induced diseases
dihydropyrimidine derivatives
Prior art date
Application number
BR112022000944A
Other languages
English (en)
Inventor
Chao Liang
Gang Deng
Jianping Wu
Linglong Kong
Xiangjun Deng
Yanping Xu
Yimin Jiang
Zhanling Cheng
Zhiguo Liu
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of BR112022000944A2 publication Critical patent/BR112022000944A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv. a presente invenção refere-se a derivados de di-hidropirimidina que são úteis no tratamento ou prevenção de infecção por hbv ou de doenças induzidas por hbv, mais particularmente de infecção crônica por hbv ou de doenças induzidas por infecção crônica por hbv, bem como suas aplicações farmacêuticas ou médicas.
BR112022000944A 2019-07-31 2020-07-30 Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv BR112022000944A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019098575 2019-07-31
PCT/CN2020/105767 WO2021018239A1 (en) 2019-07-31 2020-07-30 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
BR112022000944A2 true BR112022000944A2 (pt) 2022-03-08

Family

ID=74230250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000944A BR112022000944A2 (pt) 2019-07-31 2020-07-30 Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv

Country Status (10)

Country Link
US (1) US20220267313A1 (pt)
EP (1) EP4003987A4 (pt)
JP (1) JP2022542390A (pt)
KR (1) KR20220041121A (pt)
CN (1) CN114206862A (pt)
AU (1) AU2020321067A1 (pt)
BR (1) BR112022000944A2 (pt)
CA (1) CA3147005A1 (pt)
MX (1) MX2022001271A (pt)
WO (1) WO2021018239A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
CA2881322A1 (en) * 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2017011552A1 (en) * 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017064156A1 (en) * 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX2019010381A (es) * 2017-03-01 2020-01-21 Achillion Pharmaceuticals Inc Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos.
WO2019001420A1 (en) * 2017-06-27 2019-01-03 Janssen Pharmaceutica Nv HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING INFECTIONS WITH HEPATITIS B VIRUS

Also Published As

Publication number Publication date
CN114206862A (zh) 2022-03-18
CA3147005A1 (en) 2021-02-04
MX2022001271A (es) 2022-05-03
KR20220041121A (ko) 2022-03-31
WO2021018239A1 (en) 2021-02-04
JP2022542390A (ja) 2022-10-03
EP4003987A1 (en) 2022-06-01
EP4003987A4 (en) 2023-07-26
AU2020321067A1 (en) 2022-03-24
US20220267313A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
BR112013026427A2 (pt) inibidores de replicação viral, seu processo de preparação e seus usos terapêuticos
BR112015007616A2 (pt) inibidores de mek no tratamento de doenças por vírus
EA201391616A1 (ru) Применение тиазолидных соединений для предотвращения и лечения вирусных заболеваний, рака и заболеваний, вызванных внутриклеточными инфекциями
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112015019412A2 (pt) inibidores de bace1
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112017024727A2 (pt) cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112018000225A2 (pt) ?sais e pró-fármacos de 1-metil-d-triptofano?
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
BR112016013600A2 (pt) Peptídeo antimicrobiano e seus usos
BR112022001564A2 (pt) Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
DOP2017000116A (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
BR112017021522A2 (pt) ?composto, composição farmacêutica, uso de composto e método de tratamento de distúrbios?
BR112019007631A2 (pt) inibidores de bromodomínios
BR112022000944A2 (pt) Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]